WallStSmart
FBIO

Fortress Biotech Inc

NASDAQ: FBIO · HEALTHCARE · BIOTECHNOLOGY

$2.30
+3.60% today

Updated 2026-04-30

Market cap
$75.03M
P/E ratio
P/S ratio
1.19x
EPS (TTM)
$-0.07
Dividend yield
52W range
$2 – $5
Volume
0.8M

Fortress Biotech Inc (FBIO) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-3.0%
Last 4 quarters
Revenue YoY growth
+6.3%
Most recent quarter
EPS YoY growth
+29.8%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+8.7%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+12.6%
2025-12-31
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2025-12-31$-0.21-290.9%$3.58$4.03+12.6%
2025-11-14$0.11+1200.0%$2.49$2.61+4.8%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.11$-0.21-290.9%$16.07M+6.3%
2025-09-30$-0.01$0.11+1200.0%$17.63M+20.5%
2025-06-30$0.07$0.45+542.9%$16.41M+10.2%
2025-03-31$-0.44$-0.48-9.1%$13.14M+0.8%
2024-12-31$-0.75$-0.30+60.1%$15.12M-24.2%
2024-09-30$-0.27$-0.76-181.5%$14.63M-57.9%
2024-06-30$-1.22$-0.73+40.2%$14.90M-14.3%
2024-03-31$-1.73$-1.03+40.5%$13.03M+4.8%
2023-12-31$-1.97$-1.28+35.0%$19.95M
2023-09-30$-3.21$-0.94+70.7%$34.75M
2023-06-30$-0.23$-0.24-4.3%$17.39M
2023-03-31$-0.20$-0.21-5.0%$12.43M

Frequently asked questions

Has Fortress Biotech Inc beaten earnings estimates?
Fortress Biotech Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -3.0% over the last 3 quarters.
How does FBIO stock react to earnings?
FBIO stock has moved an average of +8.7% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is Fortress Biotech Inc's revenue growth rate?
Fortress Biotech Inc reported year-over-year revenue growth of +6.3% in its most recent quarter, with EPS growing +29.8% year-over-year.